Categoria: Adnkronos News

(Adnkronos) – LONDON, Sept. 6, 2023 /PRNewswire/ — Greenbrook, the specialist communications advisor to the investment industry, with particular expertise in private equity, hedge funds, debt, and special situations, is pleased to announce key promotions, the appointment of two new Directors and the expansion of its junior team. The firm congratulates Tashi Lassalle on being promoted to Partner only 12 months after joining Greenbrook. Tashi, renowned for her leadership roles at Actis, Lloyd's of London and the Church of England, brings rich experience to her new partnership role. She will continue spearheading talent management efforts within the organisation alongside her client commitments. Bella Lahdo, who joined the firm in 2021, has also been promoted to Consultant. Greenbrook is also pleased to welcome Alan Tovey and Ksenia Galouchko as new Directors. Alan spent 14 years as a senior journalist at Telegraph Media Group, holding roles including City News Editor and Industry Editor on the Sunday and Daily Telegraph titles. Ksenia joins from Bloomberg News, where she held editorial positions, overseeing a team of journalists responsible for European and US stocks coverage and ECM reporting. Ksenia was also a regular commentator on Bloomberg TV. Andrew Honnor, Managing Partner of Greenbrook, commented: "This news marks a significant expansion of our advisory capacity as a firm. There continues to be a very strong demand for our services. These promotions and notable hires will significantly enhance the service we can deliver to clients." Also joining the team are Christina Tang, who joins Greenbrook as a Consultant from Brunswick, and Ysabel Chen, Harriet Groves and Emelia Rice, who arrive as new Associates. Christina has advised clients in Beijing, China, on critical issues spanning regulatory concerns, corporate reputation, crisis management and public affairs. Ysabel, Harriet and Emelia are recent graduates from leading international universities, bringing a fresh perspective to the Associate team. Contact details: Demi KurbanGreenbrook+44 20 7952 2000 / dkurban@greenbrookadvisory.com  Photo – https://mma.prnewswire.com/media/2201832/Greenbrook.jpgLogo – https://mma.prnewswire.com/media/2199914/Greenbrook_Logo.jpg
 
View original content:https://www.prnewswire.co.uk/news-releases/greenbrook-announces-key-promotions-and-a-significant-expansion-of-its-senior-team-301918116.html
 

 —immediapress/pr-newswirewebinfo@adnkronos.com (Web Info)

(Adnkronos) – COPENHAGEN, Denmark, Sept. 6, 2023 /PRNewswire/ — Following convincing results from a recent In-Vitro study, the Danish biotech company, Tetra Pharm Technologies, today announces successful In-Vivo study results of its candidate compound, TPT0301.     The In-Vivo study focuses on establishing the pharmacokinetic profile of TPT0301 in fasted rats over the course of 24 hours following gastro-intestinal (GI) administration. The candidate compound was formulated using Tetra Pharm Technologies' proprietary drug delivery technology and compared against a simplistic formulation principle commonly utilized for cannabinoids. "The In-Vivo tests establish essential pharmacokinetic information, demonstrating significantly faster onset of absorption and high exposure of TPT0301 following GI administration. The combined pre-clinical package, i.e., including the previously announced In-Vitro results confirming high permeation through the mucosa in the mouth, is unique in the sense that it establishes the effectiveness of our drug delivery technology in two types of oral administration: Orally to the GI tract and sublingually, i.e., under the tongue. In the case of the latter, the fraction of dose, inevitably lost to the GI tract, will be absorbed to a high extent. The pre-clinical data therefore confirm the suitability of TPT0301 for sublingual administration while also providing us with the option to consider conventional oral administration", says Dr. Morten Allesø, Chief Scientific Officer, Tetra Pharm Technologies. The target of TPT0301 is the endocannabinoid system (ECS), which is a widespread neuromodulatory system that regulates and controls various physiological processes to maintain balance and homeostasis within the human body, such as learning and memory, emotional processing, sleep, temperature, pain control, inflammatory and immune responses, and appetite. "The demonstrated strong preclinical performance of TPT0301 increases our confidence in the upcoming First-in-Human trials. Achieving a robust blood-plasma profile is a key enabler of successful dose-finding", added Dr. Morten Allesø. Tetra Pharm Technologies is currently planning for First-in-Human trials of TPT0301 to commence in Q4 2023. "We are very excited about the outcomes of the pre-clinical studies of TPT0301 and look forward to initiating the first phase of clinical studies. Research and development are our top priority, and we will continue to invest in building our pipeline of new drug candidates targeting the endocannabinoid system (ECS) and related disease indications", says Martin Rose, CEO, Tetra Pharm Technologies. About Tetra Pharm Technologies Tetra Pharm Technologies is a Danish biopharmaceutical company established in 2018 with a vision to be a leader in research and development of pharmaceutical drugs for the treatment of diseases related to the endocannabinoid system. For more information, please visit www.tetrapharm.eu
 For further information:Martin Caspersencap@tetrapharm.eu+45 61224241 Photo – https://mma.prnewswire.com/media/2197602/Tetra_Pharm_Technologies.jpgLogo – https://mma.prnewswire.com/media/1988863/Tetra_Pharm_Technologies_Logo.jpg
   
View original content:https://www.prnewswire.co.uk/news-releases/tetra-pharm-technologies-concludes-preclinical-testing-of-tpt0301-in-preparation-of-first-in-human-clinical-trials-301913550.html
 

 —immediapress/pr-newswirewebinfo@adnkronos.com (Web Info)

(Adnkronos) – GENEVA, Sept. 6, 2023 /PRNewswire/ — The first patient has been enrolled in a UK study of large vessel de novo coronary artery disease treated with SELUTION SLR™. This is a trial initiated by physicians at the Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust, which is where the first patient was enrolled. SELUTION SLR is a novel sirolimus-eluting balloon that provides a controlled sustained release of drug, similar to a drug-eluting stent (DES). The aim of the LOVE-DEB Study (Large de-NOVo coronary artEry disease treated with sirolimus Drug Eluting Balloon: prospective evaluation of safety & efficacy of SELUTION SLR drug eluting balloon) is to evaluate the safety and efficacy of SELUTION SLR in treating native de novo coronary artery disease in larger vessels (≥2.75mm). Its primary objective is to evaluate the proportion of patients who underwent Target Lesion Revascularization (TLR) within one year of their procedure. "The LOVE-DEB Study is a unique trial in which we are assessing the safety and efficacy of sirolimus DEB in de novo disease only in the large coronary arteries in routine clinical practice. We aim to recruit 300 patients over a period of 12 months across 10 centers in the UK. I am extremely delighted that we have kick-started the study by recruiting our first patient in the study at Wigan. I am very grateful for the invaluable support from all those who are involved in this study," commented Principal Investigator Dr Abhishek Kumar, Consultant Cardiologist, Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust. "Although these centers have already adopted our novel technology in their daily practice, we are excited to see the results in this understudied important patient population, where drug-eluting stents have demonstrated a greater than 2% complication rate per year," added Jeffrey B. Jump, Chairman and CEO of MedAlliance.   MedAlliance was the first drug-eluting balloon company to receive FDA Breakthrough Designation status. Currently three IDE clinical studies are evaluating SELUTION SLR in the US: in CLTI patients with BTK disease; SFA/PPA; and coronary ISR. In addition, MedAlliance received IDE approval for de novo coronary artery lesions in January 2023. SELUTION SLR was awarded CE Mark Approval for the treatment of coronary artery disease in May 2020. This complements the substantial experience that the company has gained with the SELUTION DeNovo and SUCCESS trials in Europe & SELUTION SFA in Japan. MedAlliance's unique DEB technology involves MicroReservoirs which contain a combination of biodegradable polymer intermixed with the anti-restenotic drug sirolimus, applied as a coating on the surface of an angioplasty balloon. These MicroReservoirs provide controlled and sustained release of the drug for up to 90 days. MedAlliance's proprietary CAT™ (Cell Adherent Technology) enables the MicroReservoirs to be coated onto balloons and efficiently transferred to adhere to the vessel lumen when delivered via expansion of the balloon. SELUTION SLR is commercially available in Europe, Asia, the Middle East, and the Americas (outside USA) and most other countries where the CE Mark is recognized. Over 50,000 units have been used for patient treatments in routine clinical practice or as part of coronary clinical trials. Media Contact:Richard Kenyonrkenyon@medalliance.com+44 7831 569940 About MedAlliance MedAlliance is medical technology company which announced a staged acquisition by Cordis in October 2022. It is headquartered in Nyon, Switzerland. MedAlliance specializes in the development of ground-breaking technology and commercialization of advanced drug device combination products for the treatment of coronary and peripheral artery disease. For further information visit: www.medalliance.com
 Photo: https://mma.prnewswire.com/media/2201455/First_Patient_SELUTION_SLR_LOVE_DEB.jpgLogo: https://mma.prnewswire.com/media/1196864/MedAlliance_Logo.jpg
   
View original content:https://www.prnewswire.co.uk/news-releases/medalliance-announces-enrollment-of-first-patient-in-selution-slr-love-deb-coronary-study-301917643.html
 

 —immediapress/pr-newswirewebinfo@adnkronos.com (Web Info)

(Adnkronos) – Search engines are evolving, spurring a paradigm shift in the online travel agency business. MADRID, Sept. 6, 2023 /PRNewswire/ — Many years ago, Amuda Goueli foresaw, the imminent demise of the traditional search engine in the online travel agency (OTA) sector. The restrictive way in which an online travel agency requires its clients to already know their desired travel dates and destination, was unnatural and needed to evolve.     The Destinia founder and CEO has always maintained that the future of the OTA industry would become more personalised, with recommendations based on the unique needs of each client. Clients should have something akin to their own personal travel agent, with the widest knowledge possible using Artificial Intelligence (AI) and the ability to make recommendations and advise them, but with the prices, availability and speed of an online agency. For a long time now, clients have been clamouring for an online experience that offers all the advantages of an offline experience. Today, the future is here! On its innovative Destinia Beta platform, an ecosystem dedicated to research and development aimed at continuous evolution and growth, Destinia is introducing Desta, an AI solution designed to revolutionise the user experience of making travel arrangements. Unlike conventional virtual assistants, which can only respond to predetermined questions, Desta adapts to the needs of the client, offering personalised suggestions for destinations, hotels and travel-related services. During the beta phase, users can access Desta by registering at https://destinia.com/desta in order to try out its features first hand. According to Goueli, "The traditional search engine as we know it is becoming obsolete. Artificial Intelligence is here to stay and we should take advantage of all the benefits it has to offer in order to make people's lives better. Thanks to AI, we have finally succeeded in implementing an idea we have been visualising for many years. That future has arrived, and it is here to stay." Communications Department:press@destinia.comVisit our press room  About Destinia 
Destinia is one of the leading online travel agencies in Southern Europe. Founded in 2001, the company has more than two million clients, as well as a selection of more than a million hotels and 600 airlines. With more than 200 employees working in offices located in five different countries, Destinia has spent recent years immersed in an intense internationalisation process, which has enabled the company to sell in more than 90 countries to date. Thanks to its innovative nature, the company has been a pioneer in offering trips to space, in addition to developing technology and accepting a diverse range of payment methods, including the virtual currency bitcoin and his latest project is a virtual agent "Desta" based on AI. In 2015, Destinia created Grupo Destinia and began working in the B2B sector, making its technology and products available to third-party companies. Since then, the group has experienced exponential growth, setting new standards in the industry.   Video – https://www.youtube.com/watch?v=iBnzTMixdRM
 
View original content:https://www.prnewswire.co.uk/news-releases/destinia-revolutionises-the-sale-of-tourism-services-with-ai-301917980.html
 

 —immediapress/pr-newswirewebinfo@adnkronos.com (Web Info)

(Adnkronos) – MUNICH, Sept. 6, 2023 /PRNewswire/ — REPT BATTERO, a global leader in cutting-edge energy storage solutions, marked a historic moment with the official inauguration of its European branch at the REPT BATTERO Germany branch in Munich. Representatives from BMW and Renault, delegates from the German Overseas Chinese Association, representatives from the Labor and Economic Affairs Department of Munich, and delegates from the German Chamber of Commerce China Center, etc. attended the event. The establishment of the European branch is a strategic move that aligns with REPT BATTERO's optimistic outlook on the electrification sector across various domains such as automotive, maritime, industrial vehicles, and construction machinery. The branch aims to meet the rising demand for reliable new energy power and energy storage systems, facilitate the widespread adoption of clean energy sources, and drive innovation through local collaborations. At the same time, the European branch will become a sales, production, and technology center in the future. In the whole year of 2022, REPT BATTERO's shipments of energy storage batteries ranked third. In the future, REPT will continue to provide leading technology products for local energy storage customers in Europe, including new energy project development, household storage, industrial and commercial energy storage, and mega energy storage utility. During the event, REPT BATTERO unveiled its comprehensive Environmental, Social, and Governance (ESG) roadmap, aiming to achieve carbon neutrality in operations by 2026 and value chain Carbon Neutrality by 2035. This roadmap encompasses environmental responsibility goals, support for societal impact initiatives, and governance excellence standards, all aimed at propelling innovation and progress toward a sustainable future. REPT BATTERO's CEO Dr. Hui Cao delivered an address during the ceremony, expressing, "I'm honored to be here for the grand opening of REPT BATTERO's European branch. We are bringing you cutting-edge battery technology, a seamless industrial chain, and sustainable competitiveness. Our goal has always been to drive the green transition, achieve carbon neutrality, and promote sustainable energy globally. Today, the establishment of our European branch signifies our unwavering commitment to this mission, fortified by our leadership in advanced battery technology." At the same time, the European branch's General Manager, Ms. Diana Cheng, added, "we are thrilled to bring REPT BATTERO's expertise to Europe. Our team is dedicated to delivering top-notch energy solutions, fostering local partnerships, and contributing to the continent's sustainable energy future." The inauguration of the European branch marks a new chapter in REPT BATTERO's journey toward global leadership in the energy storage industry. The company looks forward to building strong partnerships and contributing to global transition to clean energy. ABOUT REPT BATTEROREPT BATTERO Energy Co., Ltd. (REPT BATTERO), founded in 2017, stands as TSINGSHAN Industry's inaugural investment in the new energy sector. Leveraging TSINGSHAN's rich nickel mine resources, REPT BATTERO focuses on research, development, production, and sales of new energy batteries and system-level applications. The company offers high-quality solutions for battery electric vehicles (BEV) and intelligent power storage. In the whole year of 2022, the installed volume of REPT BATTERO power batteries ranked among the Top 10, and the shipments of energy storage batteries ranked third. With plans to elevate its total capacity to over 150 GWh by 2025, REPT BATTERO is steadfast in its commitment to sustainable energy. For more information, please visit REPT BATTERO's official website and LinkedIn. Please visit https://chinarept.com/en/ and www.linkedin.com/company/reptbattero for more information. Photo – https://mma.prnewswire.com/media/2202514/REPT_BATTERO_European_Branch.jpgPhoto – https://mma.prnewswire.com/media/2202515/REPT_BATTERO_European_Branch_1.jpg
 
View original content:https://www.prnewswire.co.uk/news-releases/rept-battero-expands-global-reach-with-inauguration-of-european-branch-301918737.html
 

 —immediapress/pr-newswirewebinfo@adnkronos.com (Web Info)